Eli Lilly and Company

Eli Lilly and Company is a biopharmaceutical group founded in 1876 and headquartered in Indianapolis, Indiana, United States. It is listed on the NYSE under ticker LLY, with a share price of 1260 USD and a market cap of 1135 bn USD as of 2026-10. The company employs 47,000 people and carries a brand portfolio that includes Mounjaro, Zepbound, Verzenio, Trulicity, Jardiance and Taltz. Lilly Endowment Inc. is the largest single shareholder, holding approximately 10%.

Industry Position

Lilly operates in the biopharmaceutical industry, a segment defined by long development cycles, patent-protected product franchises and heavy dependence on clinical and regulatory outcomes. Its reported revenue trajectory places it among the larger participants in that segment: revenue moved from 24.54 bn in 2020 to 28.32 bn in 2021, 28.54 bn in 2022, 34.12 bn in 2023, 45.04 bn in 2024 and 65.2 bn in 2025. The step-up between 2023 and 2025 is the most pronounced in the disclosed series.

Market valuation has tracked that revenue path. Market cap rose from 161.5 bn in 2020 to 264.3 bn in 2021, 347.6 bn in 2022, 553.4 bn in 2023, 732.9 bn in 2024 and 910 bn in 2025, reaching 1135 bn USD as of 2026-10. The gap between the 2025 revenue base of 65.2 bn and the 2026-10 market cap of 1135 bn indicates that valuation rests on expectations beyond currently reported results.

Competitive Advantages

The brand set — Mounjaro, Zepbound, Verzenio, Trulicity, Jardiance and Taltz — spans multiple therapeutic categories, which spreads commercial exposure across more than a single product line. Scale is visible in the income statement: net income moved from 6.19 bn in 2020 to 5.58 bn in 2021, 6.24 bn in 2022 and 5.24 bn in 2023 before jumping to 10.59 bn in 2024 and 20.6 bn in 2025. The 2024–2025 increase in net income outpaced the revenue increase over the same period.

Balance-sheet capacity expanded alongside earnings. Total assets grew from 46.63 bn in 2020 to 48.81 bn in 2021, 49.49 bn in 2022, 64.01 bn in 2023, 78.72 bn in 2024 and 112.48 bn in 2025. A workforce of 47,000 supports manufacturing, research and commercial operations, and the anchor holding of approximately 10% by Lilly Endowment Inc. gives the shareholder base a stable long-term block.

Strategic Expansion

The disclosed record shows expansion expressed primarily through financial scale rather than through stated geographic or segment breakdowns. Revenue nearly tripled between 2020 (24.54 bn) and 2025 (65.2 bn), while assets rose from 46.63 bn to 112.48 bn over the same span. The asset build of roughly 33.8 bn between 2024 and 2025 alone coincides with the sharpest single-year revenue gain in the series, from 45.04 bn to 65.2 bn.

Capital markets have funded and rewarded that expansion: market cap climbed from 161.5 bn in 2020 to 1135 bn USD as of 2026-10, a multiple of roughly seven times the 2020 level. The company remains a publicly traded NYSE entity under ticker LLY, with the Endowment's approximately 10% position as the largest single holding. No segment-level revenue split by brand or geography is disclosed in the available data.

Risks & Outlook

The principal structural risk is concentration of value in forward expectations. A 1135 bn USD market cap as of 2026-10 against 2025 revenue of 65.2 bn and net income of 20.6 bn leaves limited room for disappointment in the product franchises that drive the result. The 2021–2023 period illustrates the volatility: net income fell from 6.19 bn in 2020 to 5.58 bn in 2021 and 5.24 bn in 2023 before the 2024–2025 recovery.

Brand-level exposure to Mounjaro, Zepbound, Verzenio, Trulicity, Jardiance and Taltz means that clinical, regulatory or competitive events affecting any single franchise can move group results materially. The approximately 10% Endowment stake provides ownership stability but also represents a sizeable single-holder position. Currency exposure is limited in the disclosed figures, which are reported in USD at 1 USD = 1.00 USD as of 2026-10.

On the disclosed record, the trajectory is one of accelerating revenue and income growth paired with rapid balance-sheet expansion and a valuation that embeds continued momentum. The company enters the period covered by these figures with 47,000 employees, a six-brand portfolio and a market cap of 1135 bn USD, yielding a VerityRank Score of 92/100.